- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
Drug control intersects with much of the 2030 Agenda for Sustainable Development and the UN Member State pledge to leave no one behind. In line with the 2030 Agenda, the UNDP Strategic Plan 2018-2021 and the HIV, Health and Development Strategy 2016-2021: Connecting the Dots, the International Guidelines on Human Rights and Drug Policy provide a comprehensive set of international legal standards for placing human dignity and sustainable development at the centre of Member State responses to illicit drug economies. The guidelines cover a diverse set of substantive issues ranging from development to criminal justice to public health.
The Universal Periodic Review (UPR), alongside other international and national human rights mechanisms, is an important tool for holding countries that are part of the United Nations, known as UN Member States, accountable for respecting, promoting and fulfilling the human rights of people who use drugs, as well as fulfilling the pledges countries have made through the Sustainable Development Goals (SDGs). The UPR has the potential to improve human rights everywhere, for everyone. Countries can use it to initiate national human rights processes, and it can provide a valuable opportunity for civil society to engage governments on issues relating to human rights in the context of drug policies and people who use drugs.
This report presents the results of the 2017-18 Integrated Biological and Behavioural Survey (IBBS), among people who inject drugs (PWID) in selected sites in Myanmar, including a formative assessment and population size estimations. A formative assessment was conducted in September 2017 in each site to inform the implementation of the IBBS. The assessment was conducted to assess the particulars of PWID populations in each setting, to provide information to tailor RDS and PSE methods and logistic approaches to the different PWID population and epidemic context.
In this advocacy note, IDPC discusses the WHO’s strategic role in drug policy, including progress made and ongoing gaps and challenges, and calls on the WHO and its governing bodies to engage in a more progressive and systematic way in various aspects of global drug policy to ensure more coherence with the UN system on drug policy, health, human rights, and the achievement of the Sustainable Development Goals.
The 2018 Global Overview outlines key trends across the at least 35 countries that retain the death penalty for drug offences in law, and analyses data on death sentences and executions from the last decade. Extensive examination is provided on the divergent trends witnessed in 2018 of falling execution numbers globally, and rising appeal for reimplementation of the death penalty in some countries, while considering the role public opinion plays in all of this.
The world drug problem has multiple public health dimensions encompassing vulnerability to drug use disorders and dependence, treatment and care of people with drug use disorders, reducing harm associated with drug misuse, and access to controlled medicines for medical pain relief.
In partnership with the UN Office on Drugs and Crime (UNODC), which is recognized as the leading UN entity for countering the world drug problem, the World Health Organization (WHO) has a pivotal and unique role in addressing the public health and human rights dimensions of global issues related to drugs.
The World Drug Report 2019 is again presented in five separate parts that divide the wealth of information and analysis contained in the report into individual reader-friendly booklets in which drugs are grouped by their psychopharmacological effect for the first time in the report’s history.
Drug markets are evolving at unprecedented speed. The range of substances and combinations available to users has never been wider, and the amounts produced have never been greater. Cultivation and manufacturing of heroin and cocaine have reached record highs, synthetic drugs continue to expand, and the market for new psychoactive substances (NPS) remains widely diversified with a growing interplay with traditional drug markets. The non-medical use of regulated prescription drugs (either diverted from licit channels or illicitly manufactured) is becoming a major threat: in addition to the ongoing opioid epidemic in North America, there are signs of an opioid epidemic due to the non-medical use of tramadol in North and sub Saharan Africa, as well as in the Middle East. Drug-related deaths are on the rise. At the same time, access to controlled drugs for medical purposes remains a dramatic problem in most low and middle-income countries.
Find HIV data on HIV epidemic update, epidemic update, HIV testing and counseling, Sexually Transmitted Infections (STIs), Prevention of Mother to Child Transmission (PMTCT), HIV Care and Antiretroviral Therapy (ART) Services and key populations.
Between 2010 and 2016, Asia and the Pacific registered one of the steepest declines in HIV infecti ons globally, with prevalence rates dropping by approximately 13%. Despite this overall reduction, HIV prevalence among people who inject drugs in Southeast Asia remains among the world’s highest. Regionally, seven of the ten countries with the highest rates of HIV among people who inject drugs are member states of the Association of Southeast Asian Nations (ASEAN).